NV-AACE Thyroid Cancer Symposium
November 8, 2014

Co-Sponsored by:
Dignity Health-St Rose Dominican Hospital
San Martin Campus
Alijan Conference Center
8280 W. Warm Springs Rd.
Las Vegas, NV 89113

7:15 - 8:00 am  Registration and Breakfast
8:00 – 8:05 am  Welcome
8:05 – 10:05 am  Integrative Endocrine Surgery: Use of Imaging and Molecular Markers to Improve Thyroid Cancer Surgical Outcomes

Integrative Endocrine Surgical Practice: A Three Year Report
R. Mack Harrell, MD, FACP, FACE, ECNU; AACE President
Objectives:
1. Describe the features of endocrine surgical practice integration
2. Recognize the aspects of this type of practice that could improve their own practice patterns
3. Understand the advantages of progressive integration of endocrinology, endocrine imaging and endocrine surgical practice

The Integrative Endocrine Surgery Model for the Treatment of Thyroid Malignancy
David Bimston, MD, FACS
Objectives:
1. Describe a collaborative approach between an imaging endocrinologist and an endocrine surgeon which optimizes the treatment of thyroid malignancy
2. Compose a multimodality strategy for the treatment of thyroid malignancy which utilizes a broad spectrum of available technology to optimize outcomes
3. Evaluate the role of the endocrinologist in the management of malignant thyroid disease and to discuss the impact of preoperative decision making on operative success

10:05 – 10:15 am  Q&A
10:15 – 10:35 am  Break
10:35 – 11:05 am  To Ablate or Not to Ablate: Post-op radioiodine remnant ablation in management of thyroid cancer
Shadi Abdelnour, MD, FACE
Objectives:
1. Understand the staging system for thyroid cancer
2. Review current recommendations regarding dosing for RAI remnant ablation
3. Review data comparing rTSH vs thyroid hormone withdrawal in RAI remnant ablation

11:05 – 11:15 am  Q&A

11:15 – 11:45 am  Thyroid Cancer Recurrence
Samer Nakhle, MD, FACE, ECNU
Objectives:
1. Understand the different methods of thyroid cancer surveillance
2. Management of clinical versus biochemical recurrence
3. Optimal TSH suppression

11:45 – 11:55 am  Q&A

11:55 – 12:25 pm  Tyrosine Kinase Inhibitors for Advanced Thyroid Cancer
Edwin Kingsley, MD
Objectives:
1. Review the indications for the use of tyrosine kinase inhibitors in patients with advanced thyroid cancer
2. Review the side effects and benefits of tyrosine kinase inhibitors for the treatment of advanced thyroid cancer
3. Review the recommended clinical surveillance for patients receiving therapy with tyrosine kinase inhibitors for advanced thyroid cancer

12:25 – 12:35 pm  Q&A

12:35 pm  Adjournment

*Indicates a member of both the Program Committee and faculty